Literature DB >> 27147599

Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.

Eejung Kim1, Nina Ilic1, Yashaswi Shrestha2, Lihua Zou3, Atanas Kamburov3, Cong Zhu2, Xiaoping Yang2, Rakela Lubonja2, Nancy Tran2, Cindy Nguyen2, Michael S Lawrence2, Federica Piccioni2, Mukta Bagul2, John G Doench2, Candace R Chouinard2, Xiaoyun Wu2, Larson Hogstrom2, Ted Natoli2, Pablo Tamayo4, Heiko Horn5, Steven M Corsello1, Kasper Lage5, David E Root2, Aravind Subramanian2, Todd R Golub6, Gad Getz3, Jesse S Boehm2, William C Hahn7.   

Abstract

UNLABELLED: Cancer genome characterization efforts now provide an initial view of the somatic alterations in primary tumors. However, most point mutations occur at low frequency, and the function of these alleles remains undefined. We have developed a scalable systematic approach to interrogate the function of cancer-associated gene variants. We subjected 474 mutant alleles curated from 5,338 tumors to pooled in vivo tumor formation assays and gene expression profiling. We identified 12 transforming alleles, including two in genes (PIK3CB, POT1) that have not been shown to be tumorigenic. One rare KRAS allele, D33E, displayed tumorigenicity and constitutive activation of known RAS effector pathways. By comparing gene expression changes induced upon expression of wild-type and mutant alleles, we inferred the activity of specific alleles. Because alleles found to be mutated only once in 5,338 tumors rendered cells tumorigenic, these observations underscore the value of integrating genomic information with functional studies. SIGNIFICANCE: Experimentally inferring the functional status of cancer-associated mutations facilitates the interpretation of genomic information in cancer. Pooled in vivo screen and gene expression profiling identified functional variants and demonstrated that expression of rare variants induced tumorigenesis. Variant phenotyping through functional studies will facilitate defining key somatic events in cancer. Cancer Discov; 6(7); 714-26. ©2016 AACR.See related commentary by Cho and Collisson, p. 694This article is highlighted in the In This Issue feature, p. 681. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27147599      PMCID: PMC4930723          DOI: 10.1158/2159-8290.CD-16-0160

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  55 in total

1.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 2.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

Authors:  S Y Han; H Kato; S Kato; T Suzuki; H Shibata; S Ishii; K Shiiba; S Matsuno; R Kanamaru; C Ishioka
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

Review 4.  Clinical analysis and interpretation of cancer genome data.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Mia A Levy
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

5.  Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production.

Authors:  Amanda K Tilot; Mary K Gaugler; Qi Yu; Todd Romigh; Wanfeng Yu; Robert H Miller; Thomas W Frazier; Charis Eng
Journal:  Hum Mol Genet       Date:  2014-01-26       Impact factor: 6.150

Review 6.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

7.  Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.

Authors:  Jian An; Shancheng Ren; Stephen J Murphy; Sumiya Dalangood; Cunjie Chang; Xiaodong Pang; Yangyan Cui; Liguo Wang; Yunqian Pan; Xiaowei Zhang; Yasheng Zhu; Chenji Wang; Geoffrey C Halling; Liang Cheng; William R Sukov; R Jeffrey Karnes; George Vasmatzis; Qing Zhang; Jun Zhang; John C Cheville; Jun Yan; Yinghao Sun; Haojie Huang
Journal:  Mol Cell       Date:  2015-09-03       Impact factor: 17.970

8.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

9.  A method for high-throughput gene expression signature analysis.

Authors:  David Peck; Emily D Crawford; Kenneth N Ross; Kimberly Stegmaier; Todd R Golub; Justin Lamb
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

10.  Identifying Mendelian disease genes with the variant effect scoring tool.

Authors:  Hannah Carter; Christopher Douville; Peter D Stenson; David N Cooper; Rachel Karchin
Journal:  BMC Genomics       Date:  2013-05-28       Impact factor: 3.969

View more
  55 in total

1.  The Scaffold Protein Axin Promotes Signaling Specificity within the Wnt Pathway by Suppressing Competing Kinase Reactions.

Authors:  Maire Gavagan; Erin Fagnan; Elizabeth B Speltz; Jesse G Zalatan
Journal:  Cell Syst       Date:  2020-06-17       Impact factor: 10.304

Review 2.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

3.  BET Inhibitors Potentiate Chemotherapy and Killing of SPOP-Mutant Colon Cancer Cells via Induction of DR5.

Authors:  Xiao Tan; Jingshan Tong; Yi-Jun Wang; Rochelle Fletcher; Robert E Schoen; Jian Yu; Liangfang Shen; Lin Zhang
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

Review 4.  Implementing Genome-Driven Oncology.

Authors:  David M Hyman; Barry S Taylor; José Baselga
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 5.  Functional variomics and network perturbation: connecting genotype to phenotype in cancer.

Authors:  Song Yi; Shengda Lin; Yongsheng Li; Wei Zhao; Gordon B Mills; Nidhi Sahni
Journal:  Nat Rev Genet       Date:  2017-03-27       Impact factor: 53.242

6.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

7.  Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy.

Authors:  Ryan S Nelson; Rutika J Mehta; Howard L McLeod; Christine M Walko
Journal:  JCO Precis Oncol       Date:  2019-10-01

8.  Structural basis of the atypical activation mechanism of KRASV14I.

Authors:  Asim K Bera; Jia Lu; Thomas E Wales; Sudershan Gondi; Deepak Gurbani; Andrew Nelson; John R Engen; Kenneth D Westover
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

9.  Pharmacogenomics for immunotherapy and immune-related cardiotoxicity.

Authors:  Jessica A Castrillon; Charis Eng; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

10.  Unsupervised detection of cancer driver mutations with parsimony-guided learning.

Authors:  Runjun D Kumar; S Joshua Swamidass; Ron Bose
Journal:  Nat Genet       Date:  2016-09-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.